<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04087460</url>
  </required_header>
  <id_info>
    <org_study_id>CS-CTP-PBPV-Ⅰa</org_study_id>
    <nct_id>NCT04087460</nct_id>
  </id_info>
  <brief_title>Phase Ⅰa Clinical Trial of a Pneumococcal Vaccine</brief_title>
  <acronym>PⅠCTPV</acronym>
  <official_title>A Phase Ⅰa Randomized,Double-Blind, Placebo-controlled Clinical Trial to Preliminary Evaluate the Safety and Immunogenicity of Protein Based Pneumococcal Vaccine（PBPV） in Healthy People Aged Between 18 and 49 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CanSino Biologics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henan Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CanSino Biologics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infections with Streptococcus pneumoniae often cause serious health problems, especially for
      infants and the elderly.Failure to cover all polysaccharide types is an even greater problem
      with adults than with children.

      The aim of the study is to preliminary evaluate the safety and immunogenicity of PBPV vaccine
      compared to placebo,in order to provide a basis for subsequent clinical trial design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The polysaccharide vaccine protected 60% of elderly adults who were at risk for pneumococcal
      infection.However, pneumococci are highly diverse with respect to their capsular types , and
      the polysaccharide-protein conjugate vaccines will not protect against strains of the many
      capsular types not included in the vaccine.This experimental vaccine was covered 70% of all
      pneumococcal types, Subjects will receive three doses of PBPV vaccine on day 0,60 and 120
      with different contents of 20μg,50μg,100μg each antigen in 18 to 49 years of age.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety indexes of solicited and unsolicited adverse reactions</measure>
    <time_frame>within 30 minutes,0-7 days,0-30 days post-vaccination</time_frame>
    <description>Occurrence of solicited and unsolicited reactions post each vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety indexes of lab measures</measure>
    <time_frame>day 3 and 8 post the first vaccination</time_frame>
    <description>Occurrence of abnormal changes of hematological examination,clinical chemistry test,urine test and vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety indexes of lab measures</measure>
    <time_frame>day 14 and 30 post each vaccination</time_frame>
    <description>Occurrence of abnormal changes of CK-MB,CTN,urine test and vital signs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety indexes of SAE</measure>
    <time_frame>within 180 days post vaccination</time_frame>
    <description>Occurrence of SAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogencity indexes of GMC and GMI by ELISA</measure>
    <time_frame>day 8, 14,30,60 post each vaccination</time_frame>
    <description>Geometric mean concentration(GMC) and Geometric mean increase（GMI）of anti-PspA-RX1 , anti-PspA-3296, anti-PspA-5668 and anti-PlyLD antibodies in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunogencity indexes of the seropositivity rates by ELISA</measure>
    <time_frame>day 8, 14,30,60 post each vaccination</time_frame>
    <description>the seropositivity rates of anti-PspA-RX1 , anti-PspA-3296, anti-PspA-5668 and anti-PlyLD antibodies in serum</description>
  </secondary_outcome>
  <other_outcome>
    <measure>immunogencity indexes of GMT and GMI by Opsonophagocytic assay (OPA)</measure>
    <time_frame>day30,60 post each vaccination</time_frame>
    <description>Geometric mean titer(GMT) and Geometric mean increase（GMI）of antibodies in serum</description>
  </other_outcome>
  <other_outcome>
    <measure>immunogencity indexes of neutralization test</measure>
    <time_frame>day30,60 post each vaccination</time_frame>
    <description>neutralization test activity of anti-Ply antibody in serum</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pneumonia</condition>
  <condition>Respiratory Tract Diseases</condition>
  <condition>Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Low-dose Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received three doses of PBPV with 20μg each antigen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received three doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle-dose Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received three doses of PBPV with 50μg each antigen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle-dose Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received three doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received three doses of PBPV with 100μg each antigen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received three doses of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Protein based pneumococcal vaccine(Low dose)</intervention_name>
    <description>0.2mL,Intramuscular other name:PBPV</description>
    <arm_group_label>Low-dose Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Protein based pneumococcal vaccine placebo(Low dose)</intervention_name>
    <description>0.2mL,Intramuscular other name:PBPV placebo</description>
    <arm_group_label>Low-dose Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Protein based pneumococcal vaccine(Middle dose)</intervention_name>
    <description>0.5mL,Intramuscular other name:PBPV</description>
    <arm_group_label>Middle-dose Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Protein based pneumococcal vaccine placebo(Middle dose)</intervention_name>
    <description>0.5mL,Intramuscular other name:PBPV placebo</description>
    <arm_group_label>Middle-dose Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Protein based pneumococcal vaccine(High dose)</intervention_name>
    <description>1.0mL,Intramuscular other name:PBPV</description>
    <arm_group_label>High-dose Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Protein based pneumococcal vaccine placebo(High dose)</intervention_name>
    <description>1.0mL,Intramuscular other name:PBPV placebo</description>
    <arm_group_label>High-dose Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers aged 18 to 49 years old;

          -  Willing to provide proof of identity;

          -  Able to understand and sign the informed consent;

          -  Able and willing comply with the requirements of the protocol

        Exclusion Criteria:

          -  Hypertensive volunteers with uncontrollable medications (on-site measurement: systolic
             blood pressure &gt; 140 mmHg, diastolic blood pressure &gt; 90 mmHg);

          -  Abnormal changes of laboratory measures (with clinical significance);

          -  Woman is pregnant and lactating (by urine pregnancy test)

          -  Suffered from pneumonia in the past three years;

          -  Invasive diseases caused by Streptococcus pneumoniae (such as meningitis, bacteremia,
             pericarditis, peritonitis, etc.) in the past three years;

          -  Allergic person;

          -  Any prior administration of blood products in last 3 month;

          -  Any prior administration of other research medicines in last 1 month;

          -  Plans to participate in or is participating in any other drug clinical study;

          -  Any prior administration of attenuated live vaccine in last 14 days;

          -  Any prior administration of subunit or inactivated vaccines in last 7 days;

          -  Had fever before vaccination, volunteers with temperature &gt;37.0℃ on axillary setting;

          -  According to the investigator's judgment, the volunteers have any otherfactors that
             make them unfit to participate in the clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xia Shengli</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Province Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huang Lili</last_name>
    <phone>+8613643826177</phone>
    <email>13643826177@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Suixian Center for Disease Control and Prevention</name>
      <address>
        <city>Shangqiu</city>
        <state>Henan</state>
        <zip>450016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huang Lili</last_name>
      <phone>13643826177</phone>
      <email>13643826177@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccnie</keyword>
  <keyword>PspA</keyword>
  <keyword>Pneomolysin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>In order to maintain the rights of the subject, do not open the IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

